Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors

PURPOSE: The CYP17A1 inhibitor abiraterone markedly reduces androgen precursors and is thereby effective in castration-resistant prostate cancer (CRPC). However, abiraterone increases progesterone, which can activate certain mutant androgen receptors (ARs) identified previously in flutamide-resistan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Chen, Eddy J., Sowalsky, Adam G., Gao, Shuai, Cai, Changmeng, Voznesensky, Olga, Schaefer, Rachel, Loda, Massimo, True, Lawrence D., Ye, Huihui, Troncoso, Patricia, Lis, Rosina L., Kantoff, Philip W., Montgomery, Robert B., Nelson, Peter S., Bubley, Glenn J., Balk, Steven P., Taplin, Mary-Ellen
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4359958/
https://ncbi.nlm.nih.gov/pubmed/25320358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1220
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars